VR tours of ORs reduce anxiety in pediatric patients

Providing pediatric patients with a virtual reality (VR) tour of the operating room (OR) before receiving anesthesia could reduce preoperative anxiety, according to a study published in British Journal of Surgery.

The OR can be a scary place for children and raises anxiety before receiving anesthesia. This study evaluated how a VR tour of the OR could impact preoperative anxiety to improve patient experiences and outcomes.

The study enrolled 69 pediatric patients undergoing elective surgery—35 were sorted into the control group while 34 were placed in the VR group. Control patients received standard information covering anesthesia and surgery while the VR patients watched a four-minute VR video of a penguin explaining what the operating room was. Results showed patients in the VR group experienced significantly lower levels of anxiety than the control group.

"Medical practice has been changing a great deal with the convergence of ICT—information and communications technology—and healthcare," said Sung-Hee Han, senior author of the study. "This study shows how medicine and ICT can be coordinated to achieve clinical significance. More studies and investigations are expected in line with the current trend."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.